In an ideal world we shouldn’t need drug repositioning. In an ideal world we would know exactly how drugs work, we would have precision medicine and no need to find alternative indications. But we don’t live in an ideal world, not even an almost ideal one. And so for now, there seems to be a role for drug repositioning and even more so for systematic drug repositioning (SDR). But is SDR currently done in the best possible way? What about the art of SDR -how can we integrate SDR within an organization with minimum disruption to existing processes? And could SDR evolve to become a systematic discovery tool?
Author: Vassilis Virvilis
Scientists Find New Uses for Old Drugs
Interview Of Biovista’s President Aris Persidis in Voice Of America by Jessica Berman; Monday, December 10, 2013 Here is an excerpt… “It is a very easy way to explore whether something that is therapeutically beneficial in one area and for one type of patient might be useful for another type of patient,” said Aris … Read More
GEN: Seasoned Drugs Offer Therapeutic Gold Mine
Article by Caitlin Smith GEN: Genetic Engineering & Biotechnology, May 15, 2013 … Biovista has already repositioned two drugs for the progressive form of multiple sclerosis (MS), which has had few treatment options. Most MS drugs, for treatment of the relapsing-remitting form of MS, compromise the patients’ immune systems and have significant side effects. Biovista … Read More
VA BIOTECH – Concept to Commercialization
Biovista announces that its President, Dr. Aris Persidis, will participate in the “VA BIOTECH – Concept to Commercialization” Facebook event. About VA BIOTECH – Concept to Commercialization event: Charlottesville is home to some of the most cutting edge biotechnology firms in the Country. This panel, presented in partnership with U.Va. Innovation and Charlottesville Business Innovation … Read More
Biovista and DART Therapeutics Enter into Drug Repositioning Collaboration Targeting Duchenne Muscular Dystrophy
CHARLOTTESVILLE, Virginia and CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ — DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), and Biovista, a leader in systematic drug repositioning, announced today that they have entered into a research collaboration to identify and develop novel drug repositioning candidates for DMD … Read More